Today we announced our 2026 Half-Year results & will host a webcast at 9am BST. Read more: bit.ly/46COB0Y

Today, we announced two important milestones for LYT-200: Successful End-of-Phase 1 meeting with the FDA FDA Fast Track designation for R/R high-risk #MyelodysplasticSyndromes These achievements support advancement into the Phase 2 STRIDE-MDS trial. bit.ly/4yPOjjj #HRMDS

We’re honored to be nominated for a 2026 #PrixGalien USA Award in the Incubators, Accelerators and Equity category. This recognition reflects the strength of the model we have built at PureTech to identify high-potential therapeutic opportunities, advance and de-risk them, and form dedicated companies around the most promising programs – all with the goal of bringing important new medicines to patients. We’re proud that this approach has generated a portfolio of companies and dozens of therapeutic candidates, including three that have received FDA approval. Thank you to @GalienFdn for including us among this distinguished group of nominees. prn.to/4ci9pOk

Just days after announcing the financing for our Founded Entity @CeleaTx, we're pleased to share another important milestone. The first patient has been dosed in SURPASS-IPF, the first industry-sponsored head-to-head Ph3 trial in #idiopathicpulmonaryfibrosis, evaluating deupirfenidone. Read more: bit.ly/4w2ibYN

Today marks an important milestone for PureTech and our Founded Entity @CeleaTx. We have launched Celea with a $180 million financing from a distinguished syndicate of leading healthcare investors to advance deupirfenidone. The financing enables the planned initiation of SURPASS-IPF, the first-ever industry-sponsored head-to-head Phase 3 trial in #idiopathicpulmonaryfibrosis (#IPF). Read more: bit.ly/3RgLeZk

We have built a model designed to repeatedly create, advance, & fund innovative therapeutic programs - an approach that has contributed to 3 FDA approvals & the creation of multiple Founded Entities (Seaport Therapeutics, Celea Therapeutics, Gallop Oncology, & more) Our CEO Rob Lyne and President & Co-Founder Eric Elenko recently joined the Base to Base Biotech podcast to discuss the evolution of that model, recent portfolio progress, and the many catalysts ahead. Listen here: bit.ly/43HpaJW PureTech interview begins at 31:56

Join us at #ATS2026! We’ll detail SURPASS-IPF (first industry-sponsored, head-to-head, Ph3 superiority #IPF trial) & insights on the translatability of our Ph2b data. So proud of our Celea colleagues who are advancing deupirfenidone as a potential new SOC bit.ly/4nm7a0I

Today we announced our 2025 Full Year Results and Annual Report, highlighting continued progress across our Portfolio with a sharpened strategic focus on disciplined capital allocation, operational efficiency, & long-term value creation. Join us at 9AM EDT/2PM BST as we discuss how PureTech is positioned for the future bit.ly/3R7xJL2

We’re pleased to share positive topline data from Ph1b trial of LYT-200 in relapsed/refractory (R/R) high-risk #MyelodysplasticSyndrome & R/R #AcuteMyeloidLeukemia. Our Founded Entity, Gallop Oncology, intends to discuss next steps w/ FDA in R/R HR-MDS. bit.ly/4mMpnVd

Now published in @ATSBlueEditor: full results from the Phase 2b ELEVATE IPF trial of deupirfenidone These results provide a strong scientific & clinical foundation as our Founded Entity, Celea Therapeutics, prepares to advance deupirfenidone into Phase 3. bit.ly/47Di0sM #idiopathicpulmonaryfibrosis #ipf

Today our Founded Entity @SeaportTx announced the publication of a manuscript that captures the discovery process behind the creation of GlyphAllo, further validating the Glyph platform. Initially advanced at PureTech, GlyphAllo is a hallmark of our strategy of identifying clinically validated pharmacology and overcoming key limitations through targeted innovation.

On #RareDiseaseDay, the world recognizes & supports those living w/ #rarediseases. At PureTech, this is our focus every day. Today, our team joined @Cycle4Survival to champion rare cancer research – an extension of our work at Gallop Oncology to advance LYT-200 in #AML. The same commitment drives our team at Celea Therapeutics to advance deupirfenidone for pp w/ #IPF. Both programs received Orphan Drug Designation, reflecting the need in these communities & what drives us to deliver on our mission .

Our CEO, Robert Lyne, and Co-founder & President, Eric Elenko, PhD, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Wednesday, March 11, 2026, at 11:20am EDT. bit.ly/4azs3Rw

During #RareDiseaseMonth, we’re reminded that innovation matters most where options are few. Today we're proud to share that deupirfenidone has received #OrphanDrugDesignation from the FDA and European Commission for #IPF. Read More: bit.ly/4kSPNne

On #InternationalDayofWomenandGirlsInScience, we’re proud to recognize the women shaping the future of PureTech. From advancing new possibilities in #IPF & #AML, to translating ideas into medicines, they exemplify scientific leadership. By amplifying their voices today, we aim to inspire the next gen of #WomenInSTEM #IDWGS

Our CEO, Robert Lyne, and President, Eric Elenko, presented at #JPM26, outlining PureTech’s strategy, portfolio progress, and priorities for the year ahead. Watch the presentation replay here: bit.ly/3YKFeID